China NMPA approves GSK’s Trelegy Ellipta for use in adults with uncontrolled asthma: London, UK Saturday, January 24, 2026, 09:00 Hrs [IST] GSK plc announced that China’s Nat ...
WOODTV.com on MSN
Subzero temps wreak havoc on sinuses, doctor warns
The arctic air gripping West Michigan can do more than just numb fingers and toes — it can also damage the upper respiratory ...
GSK has secured approval in China for Trelegy Ellipta as a maintenance treatment for adults with asthma, adding to its existing indication in COPD and making it the only single inhaler triple therapy ...
The corticosteroids market is driven by rising chronic diseases like asthma and COPD and innovations in drug delivery systems, enhancing treatment adherence. However, prolonged usage safety concerns ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results